Compare M&T Bank Corporation (MTB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs 10X Genomics Inc — how do they compare? M&T Bank Corporation trades at $217.44 (market cap $31.42B), while 10X Genomics Inc trades at $81.89 (market cap $10.07B). The key difference: M&T Bank Corporation is far larger — about 3.1× 10X Genomics Inc's market cap, and M&T Bank Corporation pays a 2.76% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 100 Days and 10X Genomics Inc for 92 Days on average.
| MTB | TXG | |
|---|---|---|
Market Cap | $31.42B | $10.07B |
Volume | 1,438,219 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $254.09 | $97.74 |
52-Week Low | $178.63 | $11.48 |
Typical Hold Time | 100 Days | 92 Days |
Enterprise Value | $47.77B | $9.59B |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $216.60, down 0.98% with a bearish technical outlook. The stock shows strong fundamentals with a P/E of 11.52 and net income margin of 30.85%, supported by three consecutive quarterly earnings beats. Recent news highlights dividend strength and branch expansion, while cash flow trends show operational stability despite negative net cash flow in 2025.
MTB presents a value opportunity with attractive valuation metrics and consistent profitability, though technical weakness and declining cash flow warrant caution. Analyst consensus targets $258.92 (19.5% upside) with 31% buy ratings, but bearish technical signals and rising debt levels pose near-term risks.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
